Latest 6-K stories
No 6-K stories yet.
Latest 6-K filings
- Purchased 138,046 USD shares on US Trading Venues
- Purchased 49,900 GBP shares on London Trading Venues
- Repurchase part of EUR 1 billion share buyback programme
- Share repurchase program up to DKK 15 billion
- Owns 1.2% of share capital as treasury shares
- Repurchased 492,285 shares at EUR 42.9537
- Total cost of EUR 21,145,480.12
- Shares bought between Oct 12-16, 2026
- Cost reduction plan effective immediately
- Workforce reduced by 60%
- CEO salary reduced by 40%
- Company notified of potential Unfaithful Disclosure Corporation designation
- Delayed disclosure of embezzlement suspicion from February 10, 2026
- Korea Exchange may impose demerit points under disclosure rules
- $2.9 million NCI grant awarded
- Clinical development of opaganib and CAR T-cell combination
- Focused on ultra-high-risk multiple myeloma
- Press release dated October 19, 2026
- Attached as Exhibit 99.1
- No financial results mentioned
- Discontinuation of BDR program effective October 2026
- Exhibit 99.1 details the discontinuation
- Head of Investor Relations signed the report
- Up to USD $10 million in additional DARPA support
- Support aims to accelerate quantum R&D roadmap
- Press release dated October 19, 2026
- Issued press release on October 19, 2026
- Press release included in filing as Exhibit 99.1
- Disclosure provided as per Form 6-K
- Signed by Ajay Agarwal, Company Secretary
- Board approved unaudited standalone and consolidated financial results for Q3 and half-year ended Sept 30, 2026
- Results approved at board meeting on Oct 17, 2026
- Trading window for designated persons opens Oct 20, 2026
- The Capital Group Companies, Inc. decreased below 16.00% of voting rights
- Capital Research and Management Company decreased below 16.00% of voting rights
- Total voting rights outstanding: 1,035,847,831
- Q3 2026 production results announced
- Positive permitting updates at Mt. Hamilton and San Albino
- CEO Akiba Leisman signed the report
- Share consolidation ratio 1-for-5
- Class A shares reduced from 5.5M to 1.1M
- Class B shares reduced from 366K to 73.2K
- 16 abstracts presented on oncology pipeline
- Focus on lung and breast cancer
- Presented at ESMO 2026 Congress in Madrid
- 61% overall response rate at 8 mg/kg dose
- 32% overall response rate at 6 mg/kg dose
- 2% incidence of interstitial lung disease
- CEO wrote letter to shareholders
- marks one year on Nasdaq
- no financial results provided
- Purchased 798,971 shares on 12 Oct 2026
- Purchased 805,175 shares on 13 Oct 2026
- Total shares repurchased: 83,965,539